# Ian B. Walters

> Ian B. Walters is a startup investor at SalvaRx Group PLC (Fairfield). See 0 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: [SalvaRx Group PLC](https://shizune.co/investors/profile/salvarx-group-plc)
- Location: Fairfield, United States
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ian-walters-b59825

Ian B. Walters is a startup investor at SalvaRx Group PLC in Fairfield. Dr. Ian B. Walters, M.D., MBA serves as CEO & Executive Director at SalvaRx Group plc. Dr. Walters, M.D., MBA has been Chief Medical Officer and Vice President of Clinical Development at Intensity Therapeutics, Inc. since September 2014. He serves as the Chief Executive Officer at iOx Therapeutics Limited. Dr. Walters has over 15 years ofoncology/immunology drug development experience Dr. Walters served as Senior Vice President of Translational Medicine and Corporate Development at Sorrento Therapeutics, Inc. since April 2014. He serves as the Director at iOx Therapeutics Limited. Dr. Walters first transitioned to biotech at Protein Design Labs (PDL), where he led translational work and the clinical development of multiple antibodies. From PDL he transitioned to the commercial group at Millennium Pharmaceuticals, where he co-authored two sNDAs for VELCADE(R) (Bortezomib) and launched these indications, and oversaw the medical affairs, health outcomes and pharmacoeconomics groups. Over the past seven years at Bristol-Myers Squibb (BMS), he managed physicians and helped oversee the development of numerous oncology compounds, including Brivanib (anti-VEGF/FGF), YERVOY(R) (Ipilimumab; anti-CTLA-4), SPRYCEL(R) (dasatinib, BCR-ABL), Nivolimab (anti-PD-1), anti-IGF-1R, VEGFR2 biologic, and Elotuzumab (anti-CS1), as well as biomarker and companion diagnostic work. Most recently at BMS, he had been working with the Strategic Transactions Group to evaluate and execute licensing agreements, mergers and acquisitions, clinical collaborations, and BMS's immuno-oncology strategy. After practicing medicine for several years, he was appointed to the faculty of the Rockefeller University to do translational research in immunology. Before entering the private sector, Dr. Walters was a lead investigator at the Rockefeller University and initiated cutting edge immunology research to understand the mechanism of action of several compounds. He served as a Director at 3Legs Resources plc since March 21, 2016. Dr. Walters received his Medical Degree from the Albert Einstein College of Medicine. He completed his MBA at the Wharton School of the University of Pennsylvania.

## Contacts

5 contacts available for Ian B. Walters: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/ian-b-walters?utm_source=investor_profile

## About SalvaRx Group PLC

VC Fund · Ramsey, United Kingdom

SalvaRx Group plc, formerly 3Legs Resources plc, is an investing company. The Company is engaged in drug discovery and development, focused on immune-oncology. The Company's segment is appraisal of investment targets meeting the Company's investment policy. The Company is focused on evaluation and assessment of investment opportunities inline with the investment policy. Its product is IMM60. It expects the study to evaluate approximately three treatment groups: a control arm using the standard of care (an anti-programmed death (PD)-1 therapy), a trial arm using iOX Therapeutics Ltd's drug (IMM60), and a third arm that will test the combination of IMM60 and an anti-PD1 therapy. 3Legs Management Services US LLC is the subsidiary of the Company.

1 contacts available at SalvaRx Group PLC.

| Name | Title | Profile |
| --- | --- | --- |
| Ian B. Walters | CEO & Director | — |

## FAQ

### How do I contact Ian B. Walters?

Public channels for Ian B. Walters include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co